{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:19Z","timestamp":1791478039439,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2019-I2M-2-008"],"award-info":[{"award-number":["2019-I2M-2-008"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2017YFC0907601,2017YFC0907602"],"award-info":[{"award-number":["2017YFC0907601,2017YFC0907602"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z201100005520023,Z201100005520027"],"award-info":[{"award-number":["Z201100005520023,Z201100005520027"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Several studies suggested that thrombotic and obstetric antiphospholipid syndromes could be independent identities, but few have systematically compared their clinical characteristics and prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective of this study is to identify key differences between thrombotic APS (tAPS) and obstetric APS (oAPS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center, prospective study included consecutive patients with primary antiphospholipid syndrome (APS) receiving treatment at the Peking Union Medical College Hospital during a period from 2013 to 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Screening of the database yielded a total of 244 women with positive antiphospholipid antibody (aPL). Among the 105 women with primary APS, 39 (37.14%) had isolated tAPS (ItAPS), 44 (41.90%) had isolated oAPS (IoAPS), and 9 (8.57%) had both tAPS and tAPS+oAPS. In comparison to those with IoAPS, patients with ItAPS had older age (41.92 \u00b1 11.97 vs. 33.16 \u00b1 4.22 years, <jats:italic>P<\/jats:italic> &lt; 0.01), higher rate of cardiovascular risk (at least one positive of coronary heart disease, hypertension, obesity, diabetes, and hyperlipidemia) (41.03% vs. 6.82%, <jats:italic>P<\/jats:italic> &lt; 0.01), and higher frequency of thrombocytopenia (43.59% vs. 20.45%, <jats:italic>P<\/jats:italic> &lt; 0.05). Antibody profiles were generally similar among the groups, but isolated anti-\u03b22GPI positivity was more common in patients with IoAPS (52.27% vs. 17.94% for ItAPS, <jats:italic>P<\/jats:italic> = 0.01). Triple aPL positivity was more common in patients with both tAPS and oAPS (66.67% vs. 46.15% for ItAPS vs. 25% for IoAPS, <jats:italic>P<\/jats:italic> = 0.022). Blood homocysteine was higher in patients with ItAPS (11.20 vs. 9.90 \u03bcmol\/L for IoAPS, <jats:italic>P<\/jats:italic> &lt; 0.05), but there were no differences in inflammatory markers or complements. Recurrence rate of thrombosis was higher in patients with ItAPS (33.33% vs. 2.27% for IoAPS, <jats:italic>P<\/jats:italic> \u2264 0.001) with a mean follow-up of 61 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite generally similar antibody and biochemical profiles, patients with ItAPS had much higher risk of recurrent thrombosis than IoAPS, supporting distinct mechanisms of pathogenesis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02515-w","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T06:05:45Z","timestamp":1620453945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Hui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-2858","authenticated-orcid":false,"given":"Jiu-Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"10","key":"2515_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMra002974","volume":"346","author":"JS Levine","year":"2002","unstructured":"Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346(10):752\u201363.","journal-title":"N Engl J Med."},{"key":"2515_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2005","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2005;4:295\u2013306.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2515_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","volume":"18","author":"J Alijotas-Reig","year":"2019","unstructured":"Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Saez-Comet L, Lefkou E, Mekinian A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406\u201314.","journal-title":"Autoimmun Rev."},{"issue":"8","key":"2515_CR4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3899\/jrheum.161364","volume":"44","author":"M Taraborelli","year":"2017","unstructured":"Taraborelli M, Reggia R, Dall'Ara F, Fredi M, Andreoli L, Gerosa M, et al. Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol. 2017;44(8):1165\u201372.","journal-title":"J Rheumatol."},{"issue":"2","key":"2515_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10067-018-4251-7","volume":"38","author":"P \u017digon","year":"2019","unstructured":"\u017digon P, Podov\u0161ovnik A, Ambro\u017ei\u010d A, Tom\u0161i\u010d M, Ho\u010devar A, Ga\u0161per\u0161i\u010d N, et al. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin Rheumatol. 2019;38(2):371\u20138.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2515_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","volume":"14","author":"PL Meroni","year":"2018","unstructured":"Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? Nat Rev Rheumatol. 2018;14(7):433\u201340.","journal-title":"Nat Rev Rheumatol."},{"issue":"3","key":"2515_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","volume":"49","author":"M Radin","year":"2019","unstructured":"Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum. 2019;49(3):464\u20138.","journal-title":"Semin Arthritis Rheum."},{"issue":"4","key":"2515_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/rheumatology\/kex466","volume":"57","author":"S Sciascia","year":"2018","unstructured":"Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology (Oxford). 2018;57(4):661\u20135.","journal-title":"Rheumatology (Oxford)."},{"key":"2515_CR9","doi-asserted-by":"crossref","unstructured":"Posch F, Gebhart J, Rand JH, Koder S, Quehenberger P, Pengo V, et al. Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Med. 2017;15(1):54.","DOI":"10.1186\/s12916-017-0807-7"},{"key":"2515_CR10","doi-asserted-by":"crossref","unstructured":"AWS de Souza NS, JF de Carvalho, et al. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus. 2007;16:782\u2013787.","DOI":"10.1177\/0961203307081847"},{"issue":"2","key":"2515_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","volume":"133","author":"A Matyja-Bednarczyk","year":"2014","unstructured":"Matyja-Bednarczyk A, Swadzba J, Iwaniec T, Sanak M, Dziedzina S, Cmiel A, et al. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res. 2014;133(2):173\u20136.","journal-title":"Thromb Res."},{"issue":"10","key":"2515_CR12","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/acr.21701","volume":"64","author":"CE Rodrigues","year":"2012","unstructured":"Rodrigues CE, Bonfa E, Caleiro MT, Vendramini MB, Bueno C, Lopes JB, et al. Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64(10):1576\u201383.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"2515_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.autrev.2010.10.004","volume":"10","author":"G Medina","year":"2011","unstructured":"Medina G, Gutierrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10(4):214\u20137.","journal-title":"Autoimmun Rev."},{"issue":"8","key":"2515_CR14","first-page":"1560","volume":"31","author":"JA Gir\u00f3n-Gonz\u00e1lez","year":"2004","unstructured":"Gir\u00f3n-Gonz\u00e1lez JA, Garc\u00eda del R\u00edo E, Rodr\u00edguez C, Rodr\u00edguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560\u20137.","journal-title":"J Rheumatol."},{"issue":"9","key":"2515_CR15","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/jth.13763","volume":"15","author":"R Hisada","year":"2017","unstructured":"Hisada R, Kato M, Sugawara E, Fujieda Y, Oku K, Bohgaki T, et al. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study. J Thromb Haemost. 2017;15(9):1782\u20137.","journal-title":"J Thromb Haemost."},{"key":"2515_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00001721-200203000-00013","volume":"13","author":"I Avivi","year":"2002","unstructured":"Avivi I, Lanir N, Hoffman R, Brenner B, et al. Hyperhomocysteinemia is common in patients with antiphospholipid syndrome and may contribute to expression of major thrombotic events. Blood Coagul Fibrin. 2002;13:169\u201372.","journal-title":"Blood Coagul Fibrin."},{"issue":"6","key":"2515_CR17","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1160\/TH04-03-0138","volume":"92","author":"J Kassis","year":"2004","unstructured":"Kassis J, Neville C, Rauch J, Busque L, Chang ER, Joseph L, et al. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb Haemost. 2004;92(6):1312\u20139.","journal-title":"Thromb Haemost."},{"key":"2515_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0301-2115(97)02736-X","volume":"73","author":"AT David Faden","year":"1997","unstructured":"David Faden AT, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Eur J Obstet Gyn R B. 1997;73:37\u201342.","journal-title":"Eur J Obstet Gyn R B."},{"issue":"5","key":"2515_CR19","doi-asserted-by":"publisher","first-page":"525 e1","DOI":"10.1016\/j.ajog.2017.01.026","volume":"216","author":"G Saccone","year":"2017","unstructured":"Saccone G, Berghella V, Maruotti GM, Ghi T, Rizzo G, Simonazzi G, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525 e1\u2013e12.","journal-title":"Am J Obstet Gynecol"},{"issue":"17","key":"2515_CR20","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","volume":"118","author":"V Pengo","year":"2011","unstructured":"Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714\u20138.","journal-title":"Blood."},{"issue":"6","key":"2515_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/humrep\/deh844","volume":"20","author":"S Quenby","year":"2005","unstructured":"Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod. 2005;20(6):1729\u201332.","journal-title":"Hum Reprod."},{"issue":"9","key":"2515_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/ard.2008.093179","volume":"68","author":"R Cervera","year":"2009","unstructured":"Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68(9):1428\u201332.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"2515_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0961203315617538","volume":"25","author":"M Bazzan","year":"2016","unstructured":"Bazzan M, Vaccarino A, Stella S, Sciascia S, Montaruli B, Bertero MT, et al. Patients with antiphosholipid syndrome and thrombotic recurrences: a real world observation (the Piedmont cohort study). Lupus. 2016;25(5):479\u201385.","journal-title":"Lupus."},{"issue":"3","key":"2515_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11239-017-1526-9","volume":"44","author":"G Drozdinsky","year":"2017","unstructured":"Drozdinsky G, Hadar E, Shmueli A, Gabbay-Benziv R, Shiber S. Obstetric antiphospholipid syndrome and long term arterial thrombosis risk. J Thromb Thrombolysis. 2017;44(3):371\u20135.","journal-title":"J Thromb Thrombolysis."},{"issue":"11","key":"2515_CR25","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/blood-2011-09-381913","volume":"119","author":"JC Gris","year":"2012","unstructured":"Gris JC, Bouvier S, Molinari N, Galanaud JP, Cochery-Nouvellon E, Mercier E, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012;119(11):2624\u201332.","journal-title":"Blood."},{"issue":"6","key":"2515_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","volume":"7","author":"PL Meroni","year":"2011","unstructured":"Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330\u20139.","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"2515_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2008.11.002","volume":"32","author":"V De Angelis","year":"2009","unstructured":"De Angelis V, Scurati S, Raschi E, Liutkus A, Belot A, Borghi MO, et al. Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: report of a family with multiple anti-phospholipid positive members. J Autoimmun. 2009;32(1):60\u20133.","journal-title":"J Autoimmun."},{"issue":"15","key":"2515_CR28","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","volume":"118","author":"C Agostinis","year":"2011","unstructured":"Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, et al. In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions. Blood. 2011;118(15):4231\u20138.","journal-title":"Blood."},{"issue":"7","key":"2515_CR29","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","volume":"106","author":"F Fischetti","year":"2005","unstructured":"Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106(7):2340\u20136.","journal-title":"Blood."},{"key":"2515_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1600-0897.1997.tb00198.x","volume":"37","author":"JA McIntyre","year":"1997","unstructured":"McIntyre JA, Wagenknecht DR, Sugi T, et al. Phospholipid binding plasma proteins required for antiphospholipid antibody detection\u2014an overview. Am J Reprod Immunolv. 1997;37:101\u201310.","journal-title":"Am J Reprod Immunolv."},{"issue":"9","key":"2515_CR31","first-page":"1684","volume":"21","author":"L La Rosa","year":"1994","unstructured":"La Rosa L, Meroni PL, Tincani A, Balestrieri G, Faden D, Lojacono A, et al. Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J Rheumatol. 1994;21(9):1684\u201393.","journal-title":"J Rheumatol"},{"issue":"9","key":"2515_CR32","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/art.40136","volume":"69","author":"VM Abrahams","year":"2017","unstructured":"Abrahams VM, Chamley LW, Salmon JE. Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation. Arthritis Rheumatol. 2017;69(9):1710\u201321.","journal-title":"Arthritis Rheumatol."},{"key":"2515_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fimmu.2018.00969","volume":"9","author":"M Radic","year":"2018","unstructured":"Radic M, Pattanaik D. Cellular and molecular mechanisms of anti-phospholipid syndrome. Front Immunol. 2018;9:969.","journal-title":"Front Immunol."},{"issue":"12","key":"2515_CR34","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.4049\/jimmunol.0902765","volume":"184","author":"A Lambrianides","year":"2010","unstructured":"Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol. 2010;184(12):6622\u20138.","journal-title":"J Immunol."},{"issue":"5","key":"2515_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/aji.12341","volume":"73","author":"K Poulton","year":"2015","unstructured":"Poulton K, Ripoll VM, Pericleous C, Meroni PL, Gerosa M, Ioannou Y, et al. Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol. 2015;73(5):390\u2013401.","journal-title":"Am J Reprod Immunol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02515-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T18:03:36Z","timestamp":1620497016000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02515-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02515-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the medical ethics committee of Peking Union Medical College Hospital and was conducted in accordance with the Declaration of Helsinki principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}